国泰海通：首予映恩生物-B(09606)“增持”评级目标价300.70港元

智通财经2025-04-21

智通财经APP获悉，国泰海通发布研报称，首次覆盖映恩生物-B(09606)，给予“增持”评级。公司聚焦ADC新药研发，产品达成多项License-out对外授权，布局全球市场，核心产品正在步入收获期。预计2025-2027年收入16.00/19.76/22.07亿元，综合绝对估值法及相对估值法，给予目标价300.70港元/股。国泰海通主要观点如下：DB-1303：对标Enhertu更优，全球领先...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2529844691?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-21 14:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529844691","market":"sh","top_or_hot":-1,"title":"国泰海通：首予映恩生物-B(09606)“增持”评级 目标价300.70港元","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，国泰海通发布研报称，首次覆盖映恩生物-B(09606)，给予“增持”评级。公司聚焦ADC新药研发，产品达成多项License-out对外授权，布局全球市场，核心产品正在步入收获期。预计2025-2027年收入16.00/19.76/22.07亿元，综合绝对估值法及相对估值法，给予目标价300.70港元/股。国泰海通主要观点如下：DB-1303：对标Enhertu更优，全球领先...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1281412.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国泰海通：首予映恩生物-B(09606)“增持”评级 目标价300.70港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国泰海通：首予映恩生物-B(09606)“增持”评级 目标价300.70港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-21 14:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1281412.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，国泰海通发布研报称，首次覆盖映恩生物-B(09606)，给予“增持”评级。公司聚焦ADC新药研发，产品达成多项License-out对外授权，布局全球市场，核心产品正在步入收获期。预计2025-2027年收入16.00/19.76/22.07亿元，综合绝对估值法及相对估值法，给予目标价300.70港元/股。国泰海通主要观点如下：DB-1303：对标Enhertu更优，全球领先...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1281412.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1281412.html","article_id":"2529844691","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529844691","pubTimestamp":1745216757,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，国泰海通发布研报称，首次覆盖映恩生物-B，给予“增持”评级。预计2025-2027年收入16.00/19.76/22.07亿元，综合绝对估值法及相对估值法，给予目标价300.70港元/股。国泰海通主要观点如下：DB-1303：对标Enhertu更优，全球领先跟进。HER2ADC已成为HER2+BC等领域的重要治疗手段，Enhertu在临床持续取得突破，正在引领临床用药迭代。风险调整后预计国内峰值有望达26亿元、美国峰值有望达16亿美元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"Cathay Pacific Haitong: First \"overweight\" rating to Yingen Bio-B (09606), target price of HK $300.70","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"智通财经APP获悉，国泰海通发布研报称，首次覆盖映恩生物-B(09606)，给予“增持”评级。公司聚焦ADC新药研发，产品达成多项License-out对外授权，布局全球市场，核心产品正在步入收获期。预计2025-2027年收入16.00/19.76/22.07亿元，综合绝对估值法及相对估值法，给予目标价300.70港元/股。国泰海通主要观点如下：DB-1303：对标Enhertu更优，全球领先跟进。HER2ADC已成为HER2+BC等领域的重要治疗手段，Enhertu在临床持续取得突破，正在引领临床用药迭代。DB-1303为公司开发的新一代HER2ADC，分子结构对标Enhertu，临床跟进速度全球领先、且早期临床数据展现Best-in-Class潜力。DB-1303针对子宫内膜癌适应症开拓蓝海市场，有望2025H2在美国申报上市;后续HER2+BC适应症有望2025H2在中国申报上市，HR+/HER2低表达BC适应症已在全球范围开展注册性临床、进度仅次于Enhertu。风险调整后预计国内峰值有望达26亿元、美国峰值有望达16亿美元。DB-1311：治疗潜力初现，有望引领SCLC与CRPC用药突破。B7-H3是肿瘤免疫逃逸机制中的重要靶点，治疗潜力广泛，目前全球尚无B7-H3疗法获批上市。B7-H3ADC DB-1311针对ES-SCLC、mCRPC在早期临床探索中展示出优异的疗效和安全性，研发进度位列全球第一梯队，有望引领用药突破。风险调整后预计国内峰值有望达6亿元、美国峰值有望达11亿美元。管线梯队丰富，ADC布局持续扩容公司打造了DITAC、DIBACDIMAC及DUPAC四大ADC技术平台，后续多款产品陆续步入临床阶段，有望陆续迎来POC数据。TROP2ADC DB-1305已开展联合PD-L1/VEGF双抗的临床探索，HER3ADC DB-1310针对NSCLC和BC等适应症有望2025年读出POC数据，B7-H4ADC DB-1312进展位列全球第一梯队。风险提示：临床试验进展不及预期风险;新药研发结果不及预期风险;市场推广及销售不及预期风险;国际化业务进展不及预期风险","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2529844691","isCrawlerRequest":true}

国泰海通：首予映恩生物-B(09606)“增持”评级 目标价300.70港元

精彩评论

国泰海通：首予映恩生物-B(09606)“增持”评级目标价300.70港元